Payment overview · 2025
General Payments
$433.20
16 reported records · 9 companies
Healthcare provider profile · identity verified
Samuel James Tomlinson, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · KINGSTREE, SC · NPI 1407147721
Verified facts
What the public records show
CMS Open Payments records show Samuel James Tomlinson, M.D. received $433.20 in general payments during 2025 across 16 reported records.
Biocomposites Inc accounted for 33.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Biocomposites Inc | Unresolved — no canonical attribution shown | $145.16 | 33.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $127.95 | 29.5% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $36.40 | 8.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $29.54 | 6.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.32 | 6.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.05 | 4.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.90 | 4.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.43 | 4.0% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $14.45 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $433.20 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Stimulan Normalized: stimulan |
Device | Biocomposites Inc | $145.16 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $127.95 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $36.40 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $29.54 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $29.54 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $26.32 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.02 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $14.45 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 80 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 51 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
80 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
51 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 749 | 160 |
| Atorvastatin Calcium | Atorvastatin Calcium | 679 | 157 |
| Omeprazole | Omeprazole | 582 | 120 |
| Pravastatin Sodium | Pravastatin Sodium | 561 | 115 |
| Gabapentin | Gabapentin | 396 | 82 |
| Levothyroxine Sodium | Levothyroxine Sodium | 358 | 59 |
| Metformin Hcl | Metformin Hcl | 342 | 87 |
| Lisinopril | Lisinopril | 317 | 68 |
| Hydrochlorothiazide | Hydrochlorothiazide | 313 | 75 |
| Potassium Chloride | Potassium Chloride | 302 | 68 |
| Fluticasone Propionate | Fluticasone Propionate | 291 | 109 |
| Famotidine | Famotidine | 283 | 69 |
| Furosemide | Furosemide | 278 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 262 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 261 | 51 |
| Meloxicam | Meloxicam | 247 | 74 |
| Eliquis | Apixaban | 240 | 37 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 237 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 224 | 54 |
| Metoprolol Tartrate | Metoprolol Tartrate | 223 | 48 |
| Carvedilol | Carvedilol | 219 | 38 |
| Montelukast Sodium | Montelukast Sodium | 188 | 48 |
| Trazodone Hcl | Trazodone Hcl | 186 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 184 | 42 |
| Losartan Potassium | Losartan Potassium | 169 | 45 |
| Mirtazapine | Mirtazapine | 162 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 161 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 161 | 31 |
| Januvia | Sitagliptin Phosphate | 151 | 34 |
| Sertraline Hcl | Sertraline Hcl | 137 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 136 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 131 | 42 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 131 | 34 |
| Prednisone | Prednisone | 119 | 76 |
| Valsartan | Valsartan | 116 | 22 |
| Allopurinol | Allopurinol | 115 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 111 | 29 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 107 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 105 | 49 |
| Ezetimibe | Ezetimibe | 98 | 36 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 95 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 90 | 18 |
| Memantine Hcl | Memantine Hcl | 89 | 11 |
| Azithromycin | Azithromycin | 86 | 69 |
| Levetiracetam | Levetiracetam | 84 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 81 | 14 |
| Jardiance | Empagliflozin | 80 | 18 |
| Atenolol | Atenolol | 75 | 18 |
| Donepezil Hcl | Donepezil Hcl | 73 | 13 |
| Divalproex Sodium | Divalproex Sodium | 71 | suppressed |
| Latanoprost | Latanoprost | 71 | 14 |
| Bumetanide | Bumetanide | 69 | 13 |
| Metformin Hcl Er | Metformin Hcl | 69 | 21 |
| Alendronate Sodium | Alendronate Sodium | 68 | 19 |
| Baclofen | Baclofen | 68 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 67 | 49 |
| Buspirone Hcl | Buspirone Hcl | 65 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 65 | 31 |
| Ropinirole Hcl | Ropinirole Hcl | 64 | 13 |
| Warfarin Sodium | Warfarin Sodium | 63 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 62 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 61 | 11 |
| Glipizide | Glipizide | 60 | 16 |
| Finasteride | Finasteride | 59 | 13 |
| Nifedipine Er | Nifedipine | 58 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 57 | 16 |
| Lorazepam | Lorazepam | 57 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 56 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 56 | 11 |
| Alprazolam | Alprazolam | 55 | 11 |
| Aripiprazole | Aripiprazole | 54 | suppressed |
| Linzess | Linaclotide | 51 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | 17 |
| Lactulose | Lactulose | 50 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 31 |
| Spironolactone | Spironolactone | 48 | 19 |
| Colchicine | Colchicine | 47 | 23 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 46 | 13 |
| Brimonidine Tartrate | Brimonidine Tartrate | 44 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 43 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 42 | suppressed |
| Temazepam | Temazepam | 41 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 40 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 38 | 12 |
| Ozempic | Semaglutide | 38 | suppressed |
| Risperidone | Risperidone | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Bupropion Xl | Bupropion Hcl | 36 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 36 | 14 |
| Chlorthalidone | Chlorthalidone | 33 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Naproxen | Naproxen | 33 | 23 |
| Tramadol Hcl | Tramadol Hcl | 33 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 32 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 32 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 31 | suppressed |
| Fluconazole | Fluconazole | 31 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 30 | 11 |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Glipizide Er | Glipizide | 29 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 28 | suppressed |
| Levofloxacin | Levofloxacin | 28 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 15 |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 27 | 14 |
| Irbesartan | Irbesartan | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Timolol Maleate | Timolol Maleate | 26 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 25 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | 12 |
| Meclizine Hcl | Meclizine Hcl | 23 | 12 |
| Nystatin | Nystatin | 23 | 16 |
| Clonazepam | Clonazepam | 22 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 22 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Simvastatin | Simvastatin | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 13 |
| Lovastatin | Lovastatin | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Budesonide | Budesonide | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Nyamyc | Nystatin | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Clonidine | Clonidine | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Constulose | Lactulose | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Perphenazine | Perphenazine | 12 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $433.20 · 16 records | Biocomposites Inc | FARXIGA, JARDIANCE, Kerendia, Korlym, OTEZLA, Ozempic, REPATHA, Rybelsus, Stimulan, TRELEGY ELLIPTA, VOQUEZNA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error